Susanne Lang

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Daily Hemodialysis and the Outcome of Acute Renal Failure

Helmut Schiffl, Susanne Lang, Rainald Fischer · New England Journal of Medicine · 2002 · 859 citations · Full text

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Biocompatible membranes in acute renal failure: prospective case-controlled study

Helmut Schiffl, Susanne Lang, August König et al. · The Lancet · 1994 · 317 citations

Hemodialysis, Urology, Medicine +7

Tumor necrosis factor α‐mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin

Kurt Redlich, Silvia Hayer, Andrea Maier et al. · Arthritis & Rheumatism · 2002 · 286 citations